← Back to Search

Phosphodiesterase-4 (PDE-4) Inhibitor

ARQ-154 Foam 0.3% for Scalp Psoriasis (ARRECTOR Trial)

Phase 3
Waitlist Available
Research Sponsored by Arcutis Biotherapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 8
Awards & highlights

ARRECTOR Trial Summary

This trial will test a new foam to see if it is safe and effective for treating psoriasis on the scalp and body.

Eligible Conditions
  • Scalp Psoriasis

ARRECTOR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Body Investigator Global Assessment (B-IGA) Score Change
Scalp Investigator Global Assessment (S-IGA) Score Change
Secondary outcome measures
Change From Baseline (CFB) in PSD (Psoriasis Symptoms Diary) items related to Itching, Pain, and Scaling (Questions 1, 9, and 11) aggregate score at Week 8
Change from Baseline (CFB) SI-NRS (Scalp Itch-Numeric Rating Score)
Change from Baseline (CFB) in PASI (Psoriasis Scalp Severity Index)
+11 more

ARRECTOR Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: ARQ-154 Foam 0.3%Active Control1 Intervention
ARQ-154 Foam 0.3%
Group II: ARQ-154 VehiclePlacebo Group1 Intervention
ARQ-154 Vehicle

Find a Location

Who is running the clinical trial?

Arcutis Biotherapeutics, Inc.Lead Sponsor
21 Previous Clinical Trials
7,209 Total Patients Enrolled
David Berk, MDStudy DirectorArcutis Biotherapeutics, Inc.
21 Previous Clinical Trials
8,203 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
2021. "Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05028582.
~118 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top